ColdZyme containes glycerol, water, cod trypsin, ethanol, calcium chloride, tris and menthol.
The Journal of Medical Virology has peer reviewed, approved and published the results of Enzymatica’s in vitro study on SARS-CoV-2
On July 20 Enzymatica announced the preliminary results from the in vitro study, showing that the mouth spray ColdZyme? deactivates SARS-CoV-2, the virus causing the COVID-19 pandemic. The results of the study, which also includes the common cold virus HCoV-229E, have now been published in the Journal of Medical Virology in the article “Inactivation of SARS-CoV-2 and HCoV-229E in vitro by a medical device mouth spray”.
The conclusion of the study is that the mouth spray ColdZyme can inactivate the respiratory coronaviruses SARS‐CoV‐2 and HCoV‐229E in vitro, by 98.3% and 99.9% respectively. Although the in vitro results presented cannot be directly translated into clinical efficacy, the study indicates that ColdZyme might offer a protective barrier against SARS‐CoV‐2 and a decreased risk of COVID‐19 transmission.
The Journal of Medical Virology has peer reviewed, approved and published the results of Enzymatica’s in vitro study on SARS-CoV-2
On July 20 Enzymatica announced the preliminary results from the in vitro study, showing that the mouth spray ColdZyme? deactivates SARS-CoV-2, the virus causing the COVID-19 pandemic. The results of the study, which also includes the common cold virus HCoV-229E, have now been published in the Journal of Medical Virology in the article “Inactivation of SARS-CoV-2 and HCoV-229E in vitro by a medical device mouth spray”.
The conclusion of the study is that the mouth spray ColdZyme can inactivate the respiratory coronaviruses SARS‐CoV‐2 and HCoV‐229E in vitro, by 98.3% and 99.9% respectively. Although the in vitro results presented cannot be directly translated into clinical efficacy, the study indicates that ColdZyme might offer a protective barrier against SARS‐CoV‐2 and a decreased risk of COVID‐19 transmission.
Comment